Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.43
(-0.82%)
HKD 2.43
(-0.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.87 Billion CNY | -3.34% |
| 2022 | 2.97 Billion CNY | 7.01% |
| 2021 | 2.78 Billion CNY | 11.22% |
| 2020 | 2.5 Billion CNY | 59.81% |
| 2019 | 1.56 Billion CNY | 7.23% |
| 2018 | 1.45 Billion CNY | 27.44% |
| 2017 | 1.14 Billion CNY | 2.18% |
| 2016 | 1.12 Billion CNY | 9.85% |
| 2015 | 1.02 Billion CNY | 23.75% |
| 2014 | 824.48 Million CNY | 10.05% |
| 2013 | 749.21 Million CNY | 39.44% |
| 2012 | 537.29 Million CNY | 49.71% |
| 2011 | 358.88 Million CNY | 17.99% |
| 2010 | 304.15 Million CNY | 1.78% |
| 2009 | 298.83 Million CNY | 88.59% |
| 2008 | 158.45 Million CNY | 21.53% |
| 2007 | 130.37 Million CNY | -10.1% |
| 2006 | 145.01 Million CNY | 1.48% |
| 2005 | 142.9 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.82 Billion CNY | -1.78% |
| 2024 Q2 | 2.84 Billion CNY | 0.83% |
| 2023 FY | 2.87 Billion CNY | -3.34% |
| 2023 Q2 | 3.03 Billion CNY | 6.34% |
| 2023 Q1 | 2.85 Billion CNY | -4.22% |
| 2023 Q3 | 2.94 Billion CNY | -2.8% |
| 2023 Q4 | 2.87 Billion CNY | -2.35% |
| 2022 Q4 | 2.97 Billion CNY | 2.32% |
| 2022 FY | 2.97 Billion CNY | 7.01% |
| 2022 Q3 | 2.9 Billion CNY | 7.64% |
| 2022 Q2 | 2.7 Billion CNY | -0.44% |
| 2022 Q1 | 2.71 Billion CNY | -2.42% |
| 2021 Q3 | 2.54 Billion CNY | 2.57% |
| 2021 Q2 | 2.47 Billion CNY | 2.78% |
| 2021 FY | 2.78 Billion CNY | 11.22% |
| 2021 Q1 | 2.41 Billion CNY | -3.54% |
| 2021 Q4 | 2.78 Billion CNY | 9.36% |
| 2020 Q1 | 1.46 Billion CNY | -6.23% |
| 2020 Q2 | 2.4 Billion CNY | 63.73% |
| 2020 Q3 | 2.41 Billion CNY | 0.57% |
| 2020 Q4 | 2.5 Billion CNY | 3.5% |
| 2020 FY | 2.5 Billion CNY | 59.81% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 1.52 Billion CNY | 0.0% |
| 2019 Q4 | 1.56 Billion CNY | 0.0% |
| 2019 FY | 1.56 Billion CNY | 7.23% |
| 2018 Q1 | 1.24 Billion CNY | 8.88% |
| 2018 Q4 | 1.45 Billion CNY | -0.7% |
| 2018 Q3 | 1.46 Billion CNY | 17.88% |
| 2018 FY | 1.45 Billion CNY | 27.44% |
| 2018 Q2 | 1.24 Billion CNY | 0.0% |
| 2017 FY | 1.14 Billion CNY | 2.18% |
| 2017 Q3 | 1.14 Billion CNY | -3.82% |
| 2017 Q2 | 1.19 Billion CNY | 0.0% |
| 2017 Q1 | 1.19 Billion CNY | 6.23% |
| 2017 Q4 | 1.14 Billion CNY | 0.0% |
| 2016 Q2 | 1.01 Billion CNY | 0.0% |
| 2016 Q4 | 1.12 Billion CNY | 0.0% |
| 2016 FY | 1.12 Billion CNY | 9.85% |
| 2016 Q1 | 1.01 Billion CNY | -1.01% |
| 2016 Q3 | 1.12 Billion CNY | 10.97% |
| 2015 Q3 | 1.02 Billion CNY | 2.75% |
| 2015 FY | 1.02 Billion CNY | 23.75% |
| 2015 Q2 | 992.97 Million CNY | 0.0% |
| 2015 Q4 | 1.02 Billion CNY | 0.0% |
| 2015 Q1 | 992.97 Million CNY | 20.44% |
| 2014 FY | 824.48 Million CNY | 10.05% |
| 2014 Q4 | 824.48 Million CNY | 0.0% |
| 2014 Q3 | 824.48 Million CNY | 10.14% |
| 2014 Q2 | 748.57 Million CNY | 0.0% |
| 2014 Q1 | 748.57 Million CNY | -0.09% |
| 2013 Q2 | 677.95 Million CNY | 0.0% |
| 2013 Q4 | 749.21 Million CNY | 0.0% |
| 2013 FY | 749.21 Million CNY | 39.44% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 Q2 | 424.82 Million CNY | 0.0% |
| 2012 FY | 537.29 Million CNY | 49.71% |
| 2012 Q4 | 537.29 Million CNY | 0.0% |
| 2011 FY | 358.88 Million CNY | 17.99% |
| 2011 Q2 | 338.82 Million CNY | 0.0% |
| 2011 Q4 | 358.88 Million CNY | 0.0% |
| 2010 Q2 | 314.89 Million CNY | 0.0% |
| 2010 FY | 304.15 Million CNY | 1.78% |
| 2010 Q4 | 304.15 Million CNY | 0.0% |
| 2009 FY | 298.83 Million CNY | 88.59% |
| 2008 FY | 158.45 Million CNY | 21.53% |
| 2007 FY | 130.37 Million CNY | -10.1% |
| 2006 FY | 145.01 Million CNY | 1.48% |
| 2005 FY | 142.9 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -217.003% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 87.223% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -123.486% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | -37.305% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -501.67% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 0.484% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | -1.738% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | -66.539% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -240.855% |
| SSY Group Limited | 11.96 Billion HKD | 75.96% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | -107.15% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 17.499% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 98.941% |